| Description |
HFI-419 is an insulin-regulated aminopeptidase (IRAP) inhibitor. HFI-419 has inhibitory potency for IRAP with Ki value of 0.48 μM. HFI-419 can be used for the research of cognitive and memory impairments such as Alzheimer's disease, brain trauma, and stroke[1].
|
| Related Catalog |
|
| Target |
Ki: 0.48 μM (IRAP)[1]
|
| In Vitro |
HFI-419 inhibits IRAP with a Ki value of 0.48 μM[1]. HFI-419 (1 μM) shows rapid disappearance that is associated with nonenzymatic (such as amide hydrolysis) processes[1].
|
| In Vivo |
HFI-419 (i.v, i.p; 2, 10 mg/kg) exhibits brain exposure and also exhibits potent inhibition of IRAP[1]. Animal Model: Sprague-Dawley rats[1] Dosage: 2 mg/kg, 10 mg/kg Administration: Intravenous, intraperitoneal Result: Exhibited a short apparent elimination half-life, a high plasma clearance and a large volume of distribution. Extended the apparent half-life to 4.6 h.
|
